Jiang Zhong Pharmaceutical Co.,Ltd provided earning guidance for the quarter ended March 31, 2022. for the quarter, the company is expected to have a total operating income of approximately RMB 890 million, representing a year-on-year increase of approximately 30% and the net profit attributable to shareholders of the listed company is expected to be approximately RMB180 million, representing a year-on-year increase of approximately 11%.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
26.4 CNY | -1.97% | +1.27% | +26.44% |
26/04 | Jiang Zhong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
25/03 | Jiang Zhong Pharmaceutical Co.,Ltd Proposes Cash Dividend | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.44% | 2.27B | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.79% | 248B | |
-1.31% | 219B | |
+11.15% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- 600750 Stock
- News Jiang Zhong Pharmaceutical Co.,Ltd
- Jiang Zhong Pharmaceutical Co.,Ltd Provides Earning Guidance for the Quarter Ended March 31, 2022